Coenzyme Q10 for Parkinson's disease

Jia Liu; Luning Wang; Si‐Yan Zhan; Yinyin Xia

doi:10.1002/14651858.CD008150.pub2

Scolaris Content Display Scolaris Content Display

Analysis 1.1

Comparison 1 Co Q10 versus placebo, Outcome 1 Total UPDRS score change.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Co Q10 versus placebo, Outcome 2 Motor UPDRS.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Co Q10 versus placebo, Outcome 3 Mental UPDRS.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Co Q10 versus placebo, Outcome 4 ADL UPDRS.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Co Q10 versus placebo, Outcome 5 Hoehn & Yahr.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 Co Q10 versus placebo, Outcome 6 Schwab & England (investigator).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 Co Q10 versus placebo, Outcome 7 severe viral infection.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 Co Q10 versus placebo, Outcome 8 Pharyngitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 Co Q10 versus placebo, Outcome 9 Sinusitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 Co Q10 versus placebo, Outcome 10 Flatulence.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.11

Comparison 1 Co Q10 versus placebo, Outcome 11 Back pain.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.12

Comparison 1 Co Q10 versus placebo, Outcome 12 Coughing.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.13

Comparison 1 Co Q10 versus placebo, Outcome 13 Diarrhea.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.14

Comparison 1 Co Q10 versus placebo, Outcome 14 Fall.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.15

Comparison 1 Co Q10 versus placebo, Outcome 15 Fatigue.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.16

Comparison 1 Co Q10 versus placebo, Outcome 16 Hypercholesterolemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.17

Comparison 1 Co Q10 versus placebo, Outcome 17 Number of withdrawals due to adverse effects.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Long‐term efficacy of Co Q10 versus placebo, Outcome 1 Total UPDRS score change.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.2

Comparison 2 Long‐term efficacy of Co Q10 versus placebo, Outcome 2 Motor UPDRS.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.3

Comparison 2 Long‐term efficacy of Co Q10 versus placebo, Outcome 3 Mental UPDRS.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.4

Comparison 2 Long‐term efficacy of Co Q10 versus placebo, Outcome 4 ADL UPDRS.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.5

Comparison 2 Long‐term efficacy of Co Q10 versus placebo, Outcome 5 Hoehn & Yahr.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.6

Comparison 2 Long‐term efficacy of Co Q10 versus placebo, Outcome 6 Schwab & England (investigator).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Co Q10 versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Total UPDRS score change Show forest plot	3	330	Mean Difference (IV, Fixed, 95% CI)	0.49 [‐0.64, 1.63]

1.1 300‐400mg/d VS Placebo	2	80	Mean Difference (IV, Fixed, 95% CI)	0.83 [‐0.97, 2.63]
1.2 600mg/d VS Placebo	1	50	Mean Difference (IV, Fixed, 95% CI)	0.60 [‐3.10, 4.31]
1.3 1200mg/d VS Placebo	1	58	Mean Difference (IV, Fixed, 95% CI)	‐0.25 [‐2.18, 1.67]
1.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	1.21 [‐1.64, 4.06]
2 Motor UPDRS Show forest plot	3	330	Mean Difference (IV, Fixed, 95% CI)	‐0.07 [‐0.71, 0.58]

2.1 300‐400mg/d VS Placebo	2	80	Mean Difference (IV, Fixed, 95% CI)	‐0.27 [‐0.99, 0.45]
2.2 600mg/d VS Placebo	1	50	Mean Difference (IV, Fixed, 95% CI)	0.89 [‐2.02, 3.81]
2.3 1200mg/d VS Placebo	1	58	Mean Difference (IV, Fixed, 95% CI)	0.37 [‐2.31, 3.04]
2.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.94 [‐1.17, 3.05]
3 Mental UPDRS Show forest plot	2	302	Mean Difference (IV, Fixed, 95% CI)	‐0.07 [‐0.30, 0.17]

3.1 300‐400mg/d VS Placebo	1	52	Mean Difference (IV, Fixed, 95% CI)	‐0.16 [‐0.65, 0.33]
3.2 600mg/d VS Placebo	1	50	Mean Difference (IV, Fixed, 95% CI)	‐0.13 [‐0.62, 0.37]
3.3 1200mg/d VS Placebo	1	58	Mean Difference (IV, Fixed, 95% CI)	‐0.22 [‐0.67, 0.24]
3.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.20 [‐0.24, 0.64]
4 ADL UPDRS Show forest plot	2	302	Mean Difference (IV, Fixed, 95% CI)	‐0.52 [‐1.15, 0.11]

4.1 300‐400mg/d VS Placebo	1	52	Mean Difference (IV, Fixed, 95% CI)	‐0.83 [‐2.31, 0.64]
4.2 600mg/d VS Placebo	1	50	Mean Difference (IV, Fixed, 95% CI)	‐0.29 [‐1.77, 1.19]
4.3 1200mg/d VS Placebo	1	58	Mean Difference (IV, Fixed, 95% CI)	‐1.65 [‐3.01, ‐0.29]
4.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.11 [‐0.87, 1.09]
5 Hoehn & Yahr Show forest plot	2	302	Mean Difference (IV, Fixed, 95% CI)	0.05 [‐0.05, 0.15]

5.1 300‐400mg/d VS Placebo	1	52	Mean Difference (IV, Fixed, 95% CI)	0.08 [‐0.11, 0.28]
5.2 600mg/d VS Placebo	1	50	Mean Difference (IV, Fixed, 95% CI)	0.05 [‐0.15, 0.25]
5.3 1200mg/d VS Placebo	1	58	Mean Difference (IV, Fixed, 95% CI)	0.06 [‐0.12, 0.24]
5.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.01 [‐0.20, 0.22]
6 Schwab & England (investigator) Show forest plot	2	302	Mean Difference (IV, Fixed, 95% CI)	0.30 [‐0.79, 1.39]

6.1 300‐400mg/d VS Placebo	1	52	Mean Difference (IV, Fixed, 95% CI)	0.27 [‐1.87, 2.41]
6.2 600mg/d VS Placebo	1	50	Mean Difference (IV, Fixed, 95% CI)	‐0.13 [‐2.28, 2.01]
6.3 1200mg/d VS Placebo	1	58	Mean Difference (IV, Fixed, 95% CI)	1.22 [‐0.75, 3.19]
6.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	‐0.60 [‐3.20, 2.00]
7 severe viral infection Show forest plot	2	211	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.18, 1.68]

7.1 300mg/d VS Placebo	2	157	Risk Ratio (M‐H, Fixed, 95% CI)	0.40 [0.10, 1.61]
7.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.04, 18.45]
7.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	1.46 [0.08, 26.97]
8 Pharyngitis Show forest plot	1	80	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.18, 5.89]

8.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.04, 17.64]
8.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.04, 18.45]
8.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	1.46 [0.08, 26.97]
9 Sinusitis Show forest plot	2	222	Risk Ratio (M‐H, Fixed, 95% CI)	0.75 [0.30, 1.92]

9.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	1.36 [0.08, 24.76]
9.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
9.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	1.46 [0.08, 26.97]
9.4 2400mg/d VS Placebo	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.21, 1.82]
10 Flatulence Show forest plot	1	80	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.06, 1.04]

10.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.09 [0.00, 1.96]
10.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.5 [0.06, 4.47]
10.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.02, 3.59]
11 Back pain Show forest plot	2	222	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.43, 2.35]

11.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.48 [0.05, 4.27]
11.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.02, 3.34]
11.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.14, 7.70]
11.4 2400mg/d VS Placebo	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	1.5 [0.44, 5.09]
12 Coughing Show forest plot	2	222	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.21, 1.36]

12.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.24 [0.02, 3.19]
12.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.02, 3.34]
12.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.02, 3.59]
12.4 2400mg/d VS Placebo	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.8 [0.22, 2.86]
13 Diarrhea Show forest plot	3	353	Risk Ratio (M‐H, Fixed, 95% CI)	1.39 [0.62, 3.16]

13.1 300mg/d VS Placebo	2	157	Risk Ratio (M‐H, Fixed, 95% CI)	3.51 [0.68, 18.19]
13.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.04, 18.45]
13.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	1.46 [0.08, 26.97]
13.4 2400mg/d VS Placebo	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.27, 2.61]
14 Fall Show forest plot	2	222	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.22, 1.35]

14.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.09, 5.51]
14.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.10 [0.00, 2.05]
14.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.02, 3.59]
14.4 2400mg/d VS Placebo	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.8 [0.22, 2.86]
15 Fatigue Show forest plot	2	222	Risk Ratio (M‐H, Fixed, 95% CI)	0.32 [0.12, 0.85]

15.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.48 [0.05, 4.27]
15.2 600mg/d VS Placebo	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.02, 3.34]
15.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.10 [0.00, 2.13]
15.4 2400mg/d VS Placebo	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.38 [0.10, 1.36]
16 Hypercholesterolemia Show forest plot	2	223	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.04, 0.44]

16.1 300mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.12 [0.01, 1.07]
16.2 600mg/d VS Placebo	1	26	Risk Ratio (M‐H, Fixed, 95% CI)	0.05 [0.00, 0.99]
16.3 1200mg/d VS Placebo	1	29	Risk Ratio (M‐H, Fixed, 95% CI)	0.13 [0.01, 1.21]
16.4 2400mg/d VS Placebo	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.03, 2.18]
17 Number of withdrawals due to adverse effects Show forest plot	4	381	Risk Ratio (M‐H, Fixed, 95% CI)	0.61 [0.23, 1.62]

Comparison 1. Co Q10 versus placebo

Ir a la tabla de la revisión

Comparison 2. Long‐term efficacy of Co Q10 versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Total UPDRS score change Show forest plot	2	222	Mean Difference (IV, Fixed, 95% CI)	‐0.27 [‐2.61, 2.07]

1.1 300mg/d VS Placebo	1	26	Mean Difference (IV, Fixed, 95% CI)	‐3.18 [‐10.49, 4.13]
1.2 600mg/d VS Placebo	1	25	Mean Difference (IV, Fixed, 95% CI)	‐1.17 [‐8.50, 6.16]
1.3 1200mg/d VS Placebo	1	29	Mean Difference (IV, Fixed, 95% CI)	‐5.3 [‐12.03, 1.43]
1.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	1.21 [‐1.64, 4.06]
2 Motor UPDRS Show forest plot	2	222	Mean Difference (IV, Fixed, 95% CI)	0.33 [‐1.41, 2.06]

2.1 300mg/d VS Placebo	1	26	Mean Difference (IV, Fixed, 95% CI)	‐0.66 [‐6.09, 4.77]
2.2 600mg/d VS Placebo	1	25	Mean Difference (IV, Fixed, 95% CI)	‐0.07 [‐5.51, 5.37]
2.3 1200mg/d VS Placebo	1	29	Mean Difference (IV, Fixed, 95% CI)	‐1.93 [‐6.92, 3.06]
2.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.94 [‐1.17, 3.05]
3 Mental UPDRS Show forest plot	2	222	Mean Difference (IV, Fixed, 95% CI)	‐0.11 [‐0.44, 0.21]

3.1 300mg/d VS Placebo	1	26	Mean Difference (IV, Fixed, 95% CI)	‐0.36 [‐1.23, 0.51]
3.2 600mg/d VS Placebo	1	25	Mean Difference (IV, Fixed, 95% CI)	‐0.55 [‐1.42, 0.32]
3.3 1200mg/d VS Placebo	1	29	Mean Difference (IV, Fixed, 95% CI)	‐0.57 [‐1.37, 0.23]
3.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.20 [‐0.24, 0.64]
4 ADL UPDRS Show forest plot	2	222	Mean Difference (IV, Fixed, 95% CI)	‐0.45 [‐1.30, 0.40]

4.1 300mg/d VS Placebo	1	26	Mean Difference (IV, Fixed, 95% CI)	‐2.2 [‐5.20, 0.80]
4.2 600mg/d VS Placebo	1	25	Mean Difference (IV, Fixed, 95% CI)	‐0.72 [‐3.73, 2.29]
4.3 1200mg/d VS Placebo	1	29	Mean Difference (IV, Fixed, 95% CI)	‐3.12 [‐5.88, ‐0.36]
4.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.11 [‐0.87, 1.09]
5 Hoehn & Yahr Show forest plot	2	222	Mean Difference (IV, Fixed, 95% CI)	0.08 [‐0.04, 0.21]

5.1 300mg/d VS Placebo	1	26	Mean Difference (IV, Fixed, 95% CI)	0.14 [‐0.14, 0.42]
5.2 600mg/d VS Placebo	1	25	Mean Difference (IV, Fixed, 95% CI)	0.13 [‐0.15, 0.41]
5.3 1200mg/d VS Placebo	1	29	Mean Difference (IV, Fixed, 95% CI)	0.11 [‐0.15, 0.37]
5.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	0.01 [‐0.20, 0.22]
6 Schwab & England (investigator) Show forest plot	2	222	Mean Difference (IV, Fixed, 95% CI)	1.11 [‐0.75, 2.97]

6.1 300mg/d VS Placebo	1	26	Mean Difference (IV, Fixed, 95% CI)	3.09 [‐1.66, 7.84]
6.2 600mg/d VS Placebo	1	25	Mean Difference (IV, Fixed, 95% CI)	0.95 [‐3.82, 5.72]
6.3 1200mg/d VS Placebo	1	29	Mean Difference (IV, Fixed, 95% CI)	4.43 [0.05, 8.81]
6.4 2400mg/d VS Placebo	1	142	Mean Difference (IV, Fixed, 95% CI)	‐0.60 [‐3.20, 2.00]

Comparison 2. Long‐term efficacy of Co Q10 versus placebo

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet

Scolaris Content Display Scolaris Content Display

Scolaris Language Selector Scolaris Language Selector

Scolaris Content Display Scolaris Content Display

Instituciones a las que se accedió previamente

Scolaris Content Display Scolaris Content Display

Usuarios institucionales

Instituciones a las que se accedió previamente

Otras opciones de acceso

	Idioma de la Revisión Cochrane Escoja su idioma de preferencia para las revisiones Cochrane y otros contenidos. Las secciones sin una traducción aparecerán en inglés.

	Idioma de la web Escoja su idioma de preferencia para la web de la Biblioteca Cochrane.

Idioma de la Revisión Cochrane

Idioma de la web

Contenido relacionado

Revisiones y protocolos relacionados

Copiar o descargar referencia

Idioma de la Revisión Cochrane

Idioma de la web

Instituciones a las que se accedió previamente

Usuarios institucionales

Instituciones a las que se accedió previamente

Otras opciones de acceso